Department of Environmental Science and Bioscience Kristianstad University Kristianstad Sweden.
Department of Clinical Sciences Lund UniversitySkåne University Hospital Malmö Sweden.
J Am Heart Assoc. 2022 Feb 15;11(4):e023018. doi: 10.1161/JAHA.121.023018. Epub 2022 Feb 3.
Background Five classic thrombophilias have been recognized: factor V Leiden (rs6025), the prothrombin G20210A variant (rs1799963), and protein C, protein S, and antithrombin deficiencies. This study aimed to determine the thrombotic risk of classic thrombophilias in a cohort of middle-aged and older adults. Methods and Results Factor V Leiden, prothrombin G20210A and protein-coding variants in the (protein C), (protein S), and (antithrombin) anticoagulant genes were determined in 29 387 subjects (born 1923-1950, 60% women) who participated in the Malmö Diet and Cancer study (1991-1996). The Human Gene Mutation Database was used to define 68 disease-causing mutations. Patients were followed up from baseline until the first event of venous thromboembolism (VTE), death, or Dec 31, 2018. Carriership (n=908, 3.1%) for disease-causing mutations in the , , and genes was associated with incident VTE: Hazard ratio (HR) was 1.6 (95% CI, 1.3-1.9). Variants not in Human Gene Mutation Database were not linked to VTE (HR, 1.1; 95% CI, 0.8-1.5). Heterozygosity for rs6025 and rs1799963 was associated with incident VTE: HR, 1.8 (95% CI, 1.6-2.0) and HR, 1.6 (95% CI, 1.3-2.0), respectively. The HR for carrying 1 classical thrombophilia variant was 1.7 (95% CI, 1.6-1.9). HR was 3.9 (95% CI, 3.1-5.0) for carriers of ≥2 thrombophilia variants. Conclusions The 5 classic thrombophilias are associated with a dose-graded risk of VTE in middle-aged and older adults. Disease-causing variants in the , , and genes were more common than the rs1799963 variant but the conferred genetic risk was comparable with the rs6025 and rs1799963 variants.
已确认五种经典血栓形成倾向:因子 V 莱顿突变(rs6025)、凝血酶原 G20210A 变异(rs1799963)和蛋白 C、蛋白 S、抗凝血酶缺乏。本研究旨在确定经典血栓形成倾向在中年和老年人队列中的血栓形成风险。
在参加马尔默饮食与癌症研究(1991-1996 年)的 29387 名受试者(出生于 1923-1950 年,60%为女性)中,确定了因子 V 莱顿、凝血酶原 G20210A 和编码蛋白的变异(蛋白 C)、(蛋白 S)和(抗凝血酶)抗凝基因。人类基因突变数据库用于定义 68 种致病突变。患者从基线开始随访,直至发生静脉血栓栓塞症(VTE)、死亡或 2018 年 12 月 31 日。在、和基因中携带致病突变(n=908,3.1%)与 VTE 事件相关:危险比(HR)为 1.6(95%CI,1.3-1.9)。人类基因突变数据库中未发现的变异与 VTE 无关(HR,1.1;95%CI,0.8-1.5)。rs6025 和 rs1799963 的杂合性与 VTE 事件相关:HR,1.8(95%CI,1.6-2.0)和 HR,1.6(95%CI,1.3-2.0)。携带 1 种经典血栓形成倾向变异的 HR 为 1.7(95%CI,1.6-1.9)。携带≥2 种血栓形成倾向变异的 HR 为 3.9(95%CI,3.1-5.0)。
在中年和老年人中,五种经典血栓形成倾向与剂量梯度的 VTE 风险相关。、和基因中的致病变异比 rs1799963 变异更为常见,但所带来的遗传风险与 rs6025 和 rs1799963 变异相当。